Vancouver-based psychedelics company Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) is set to enter the American market after acquiring a Canadian mental health company with psychedelic-assisted therapy clinics in Arizona and Utah.
On Tuesday, the psychedelics-focused company announced it entered into an agreement to acquire all of the issued and outstanding common shares of Novamind Inc. (CSE: NM) (OTCQB: NVMDF) (FSE: HN2) for $26.2 million.
Toronto-headquartered Novamind provides ketamine-assisted psychotherapy at its six clinics –with two more to be opened soon– in Utah through its wholly-owned subsidiary Cedar Psychiatry. It also operates two clinics in Arizona via its subsidiary Phoenix Clinics.
Once the transaction closes around June, the combined company will operate 13 psychedelic-assisted therapy clinics in the United States and Canada as well as four clinical research sites and one bioanalytical lab.
Under the agreement, shareholders of Novamind will receive 0.84 of a common share of Numinus for each Novamind share held at a price of $0.44 per Novamind share. After the transaction finishes Novamind shareholders will hold around 18 per cent ownership.
Numinus expects the acquisition will bolster its financial performance and grow its annual revenue more than five times.
The company will host MDMA clinical trials in partnership with the Multidisciplinary Association of Psychedelic Studies Public Benefit Corporation, psilocybin trials with the Usona Institute, LSD research with MindMed and ketamine in partnership with the University of Utah.
It will provide services such as ketamine-assisted psychotherapy, esketamine treatments, transcranial magnetic stimulation, talk therapy, group therapy, medication management, psychedelic palliative care and neurological care.
— Payton Nyquvest (@paytonnyquvest) April 12, 2022
The Novamind acquisition presents a transformational opportunity for Numinus to launch a strong U.S. platform through eight established, reputable, efficiently operating and revenue-producing clinics,” Numinus CEO Payton Nyquvest said.
“We prioritize working with the best partners in this industry and Novamind’s U.S. market presence, complementary client programming and respected clinical research capabilities allow us to accelerate our strategic growth plans and broaden access to healing and wellness.”
Numinus Bioscience, the company’s research branch, is licensed by Health Canada to possess, produce, sell, export, research and access a wide range of psychedelic drugs such as DMT, ketamine, LSD, MDMA, mescaline, psilocin, ayahuasca and San Pedro.
Numinus currently operates clinics in Vancouver, Montreal and Toronto.
Novamind CEO Yaron Conforti said the transaction offers significant value for Novamind’s shareholders and provides opportunities for its employees, patients and research partners.
“The combination of Novamind’s network of mental health clinics and research sites in the U.S. and Numinus’ leadership in psychedelic-assisted psychotherapy in Canada creates a best-in-class company,” he said.
“The combined entity is supported with over $50 million in pro-forma capital and positioned with distinct capabilities to serve a growing and diverse group of stakeholders. We are excited to join Numinus, a true leader in mental health innovation.”